{"id":"moxifloxacin-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Corneal staining"},{"rate":null,"effect":"Increased intraocular pressure (with prolonged corticosteroid use)"}]},"_chembl":{"chemblId":"CHEMBL1200735","moleculeType":"Small molecule","molecularWeight":"437.90"},"_dailymed":{"setId":"62ff1da3-7998-676a-e053-2991aa0a4a9f","title":"DEX-MOXI (DEXAMETHASONE PHOSPHATE - MOXIFLOXACIN) INJECTION, SOLUTION [IMPRIMIS NJOF, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Moxifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, preventing bacterial DNA replication and transcription. Dexamethasone acts as a glucocorticoid receptor agonist, reducing inflammation and immune-mediated tissue damage. This combination targets both the infectious agent and the inflammatory response, commonly used in ophthalmic formulations for bacterial infections with associated inflammation.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that suppresses inflammation and immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T06:16:17.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis with inflammation"},{"name":"Post-operative ocular inflammation and infection prophylaxis"},{"name":"Bacterial keratitis with inflammatory component"}]},"trialDetails":[{"nctId":"NCT07305987","phase":"PHASE3","title":"PRO-232 in Patients Subjected to Cataract Surgery","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-10-27","conditions":"Cataract Extraction","enrollment":134},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05917340","phase":"PHASE3","title":"Intensified Short Course Regimen for TBM in Adults","status":"NOT_YET_RECRUITING","sponsor":"Indian Council of Medical Research","startDate":"2024-03","conditions":"Tuberculous Meningitis","enrollment":372},{"nctId":"NCT04521140","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2020-10-16","conditions":"Corneal Edema, Corneal Defect, Corneal Transplant","enrollment":36},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT05665270","phase":"PHASE4","title":"A Study for Post op Inflammation After Cataract Surgery","status":"UNKNOWN","sponsor":"Wyse Eyecare","startDate":"2023-01-30","conditions":"Cataract","enrollment":40},{"nctId":"NCT05331859","phase":"PHASE1","title":"Topical Insulin Versus Autologous Serum After Corneal Surgeries","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-05","conditions":"Corneal Epithelial Wound","enrollment":250},{"nctId":"NCT03580473","phase":"PHASE2","title":"Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification","status":"COMPLETED","sponsor":"EMS","startDate":"2020-02-27","conditions":"Ocular Inflammation, Cataract","enrollment":118},{"nctId":"NCT04273282","phase":"PHASE4","title":"A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2019-12-16","conditions":"Cataract","enrollment":31},{"nctId":"NCT04205916","phase":"PHASE4","title":"A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery","status":"RECRUITING","sponsor":"Ophthalmic Consultants of Long Island","startDate":"2019-11-04","conditions":"Patient Preference","enrollment":50},{"nctId":"NCT01874561","phase":"PHASE1","title":"Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization","status":"COMPLETED","sponsor":"Achieve Life Sciences","startDate":"2013-05","conditions":"Cardiac Conduction and Repolarization","enrollment":155},{"nctId":"NCT02816905","phase":"PHASE4","title":"Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery","status":"COMPLETED","sponsor":"Cairo University","startDate":"2015-10","conditions":"Intraocular Pressure","enrollment":40},{"nctId":"NCT01546402","phase":"PHASE4","title":"Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2011-05","conditions":"Macular Edema, Cystoid, Vision Disorders, Diabetic Macular Edema","enrollment":20},{"nctId":"NCT01515826","phase":"PHASE3","title":"VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2014-03","conditions":"Cataracts","enrollment":""},{"nctId":"NCT01859702","phase":"PHASE4","title":"Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-04","conditions":"Cataract","enrollment":36},{"nctId":"NCT00579020","phase":"PHASE2","title":"A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2007-12","conditions":"Corneal Infiltrates","enrollment":144},{"nctId":"NCT00750633","phase":"PHASE3","title":"A Phase III Study of an Otic Formulation in Acute Otitis Externa","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-06","conditions":"Acute Otitis Externa","enrollment":990},{"nctId":"NCT00732446","phase":"PHASE3","title":"Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2008-08","conditions":"Blepharitis, Conjunctivitis, Keratitis","enrollment":100},{"nctId":"NCT00870103","phase":"PHASE4","title":"Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":"Cataract","enrollment":64},{"nctId":"NCT00330824","phase":"NA","title":"Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Post Operative Inflammation in LASIK Surgery","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2006-04","conditions":"Post Lasik Surgery Inflammation","enrollment":64},{"nctId":"NCT00331084","phase":"NA","title":"Efficacy/Safety of Antibiotic Steroid Combination in Prevention of Postoperative Inflammation in Cataract Surgery","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2006-04","conditions":"Inflammation Following Cataract Surgery","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"moxifloxacin / dexamethasone","genericName":"moxifloxacin / dexamethasone","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while dexamethasone is a corticosteroid that suppresses inflammation and immune responses. Used for Bacterial conjunctivitis with inflammation, Post-operative ocular inflammation and infection prophylaxis, Bacterial keratitis with inflammatory component.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}